CA2708489A1 — Use of cabazitaxel and a prednisone or a prednisolone in the treatment of prostate cancer
Assigned to Aventis Pharma SA · Expires 2011-04-29 · 15y expired
What this patent protects
The invention relates to an antitumoral pharmaceutical combination comprising cabazitaxel of formula: (see above formula) and prednisone or prednisolone, these two agents possibly being in base form, or in the form of a hydrate or a solvate, intended for treating metastatic p…
USPTO Abstract
The invention relates to an antitumoral pharmaceutical combination comprising cabazitaxel of formula: (see above formula) and prednisone or prednisolone, these two agents possibly being in base form, or in the form of a hydrate or a solvate, intended for treating metastatic prostate cancer, especially for patients who are not catered for by a taxane-based treatment.
Drugs covered by this patent
- Jevtana Kit (cabazitaxel) · Accord Hlthcare
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.